Core Viewpoint - The approval of the first invasive brain-computer interface (BCI) medical device by the National Medical Products Administration marks a significant milestone in clinical applications, with the company BoRuiKang Medical Technology (Shanghai) Co., Ltd. initiating its IPO process simultaneously [1][4]. Group 1: Product Overview - The approved product consists of a brain-computer interface implant, an electrode kit, a signal transceiver, a pneumatic glove device, a surgical toolkit, and software for decoding brain signals and clinical management [3]. - It is designed for patients aged 18 to 60 with cervical spinal cord injuries resulting in quadriplegia, specifically those with stable conditions for at least six months [3]. Group 2: Technology and Innovation - The NEO system, developed in collaboration with Tsinghua University, utilizes a minimally invasive approach with a wireless power and communication design, avoiding direct contact with brain tissue [4][5]. - Clinical trials have shown significant improvements in hand function for participants, with some achieving independent grasping and basic daily activities [5]. Group 3: Market Growth - The global implanted BCI market is projected to grow from approximately $153 million in 2026 to about $252 million by 2030, with a compound annual growth rate (CAGR) of around 13% [6]. - The Chinese BCI market is expected to reach approximately 46 billion yuan in 2026, with long-term projections suggesting it could exceed 120 billion yuan by 2040 [6]. Group 4: Policy and Industry Dynamics - The BCI technology has been included in China's "14th Five-Year Plan," with government support aimed at achieving key technological breakthroughs by 2027 [7]. - The competitive landscape is intensifying, with BoRuiKang leading in semi-invasive technology while other companies pursue fully invasive approaches [7]. Group 5: Future Outlook - The BCI industry is transitioning from research to commercialization, with BoRuiKang's NEO system positioning Chinese enterprises favorably in this emerging market [8]. - The potential for large-scale application of BCI technology could create new opportunities in the medical industry, particularly for the rehabilitation of millions of spinal cord injury patients [8].

Company Overview - Brain-computer interface company, BoRuiKang Technology (Shanghai) Co., Ltd., has completed its IPO counseling registration on February 4, 2026, with CITIC Securities as the counseling broker, marking the official start of its Sci-Tech Innovation Board IPO process [1][2][3] - Established in November 2011, BoRuiKang's core team includes experts from Tsinghua University's Neural Engineering Laboratory and clinical neuroscience, focusing on the research, production, and technical services of brain-computer interface systems [3][4] - The company has developed products for clinical diagnosis and research education, including digital EEG machines and transcranial electrical stimulation systems, with some products already receiving medical device registration [3][4] Product Development - BoRuiKang's flagship product, the NEO wireless minimally invasive brain-computer interface system, is the world's first to use an epidural implant with fully wireless transmission design [3][4] - NEO employs a "semi-invasive" technique, implanting coin-sized electrodes beneath the skull but outside the dura mater, allowing proximity to neurons without direct contact, thus avoiding damage to neural tissue [4] - The NEO system has undergone successful clinical trials, with 32 patients having completed implantation across 11 hospitals, achieving a 100% success rate in primary clinical endpoints [4][5] Regulatory Progress - NEO is set to submit a Class III innovative medical device registration application to the National Medical Products Administration, potentially becoming the first marketed implantable brain-computer interface product in China [5] - The product's first version, NEO 1.0, is expected to be followed by a 2.0 version that will include additional features such as language decoding and small limb decoding [5] Financial Backing and Valuation - BoRuiKang has completed multiple rounds of financing, with notable investors including Sequoia China and Baidu Ventures, achieving a post-investment valuation of 3.5 to 4 billion yuan by the end of 2025 [5][6] - The company has raised a total of 1.2 million yuan in angel funding and 30 million yuan in Pre-A funding, among other financing rounds [5] Industry Context - The brain-computer interface industry is experiencing significant growth opportunities in China, supported by favorable policies and market conditions [9][10] - The Ministry of Industry and Information Technology and other departments have included brain-computer interfaces in key future industry cultivation, with projections indicating the market could exceed 120 billion yuan by 2040 [10]